Two drugs treating gastrointestinal illnesses have received FDA approval, Phathom Pharmaceuticals said May 3.
Voquezna Triple Pak and Voquezna Dual Pak both treat helicobacter pylori and are supplied in blister packs.
A commercial launch is expected in the third quarter of 2022.